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Abstract 
Staphylococcus  intermedius is  part  of  the
normal skin and oral flora of dogs. Case reports
of human infections are rare, but the true inci-
dence is unknown because the pathogen is fre-
quently  misidentified  as  Staphylococcus
aureus. Reported cases range from soft tissue
infections  to  brain  abscess.  Most  reported
cases  in  humans  have  been  related  to  dog
exposure. We report a case of a 73 year old
female  with  S.  intermedius surgical  wound
infection one month following a left elbow total
arthroplasty. This is the first reported human
case of S. intermedius infection of a mechani-
cal prosthesis. The presumed source of infec-
tion  was  the  patient’s  dog.  The  patient  was
treated  with  vancomycin,  then  switched  to
cefazolin  and  rifampin  once  susceptibilities
were  known.  Case  reports  suggest  that
patients  generally  respond  well  to  tailored
antibiotics  with  complete  or  near-complete
recovery. S. intermedius should be included in
the differential diagnosis of invasive infection
amongst patients with close contact with dogs. 
Introduction
Staphylococcus  intermedius was  first
described  in  1976  as  a  coagulase-positive
Staphylococcus. It has since been identified as
part of normal skin and mucosal flora in a vari-
ety of animals, including dogs, cats, pigeons,
minks, horses, foxes, raccoons, goats, and gray
squirrels.1 It is the predominant cause of skin
and soft tissue infection in dogs,2-6but has only
rarely been isolated from humans. However,
there are an increasing number of case reports
documenting serious invasive infections with
S. intermedius in humans including infected
dog  bite  wounds,4,7-11 bacteremia,1 pneumo-
nia,12 sinusitis,13 otitis  externa,14 nail  bed
infection,15 mastoiditis,16 brain abscess,17 skin
abscess,18 and bacteremia complicated by sep-
tic arthritis and iliacus abscess.19 There has
also been one reported outbreak of S. inter-
medius related food intoxication involving over
265  cases  in  the  western  United  States  in
1991.20 More  recently,  the  discovery  of
Staphylococcus pseudintermedius in 2005 has
led to the reclassification of isolates formerly
identified as S. intermedius based on molecu-
lar  techniques.21 The  S.  intermedius group
(SIG) was divided into S. intermedius, S. pseud-
intermedius,  and  Staphylococcus  delphini.22
According to this new grouping, S. pseudinter-
medius, and not S. intermedius, is the species
that colonizes and causes infections in dogs
and cats, and S. intermedius mainly colonizes
pigeons.22,23 Thus,  older  reports  of  S.  inter-
medius, particularly in animal bites, are often
now viewed as S. pseudintermedius.24
Because  human  infection  with  coagulase
positive Staphylococci other than S. aureus is
rare, pitfalls in identification of SIG organisms
abound. The true incidence of SIG infections is
unknown but likely higher than reported since
laboratories  tend  to  presumptively  identify
coagulase-positive Staphylococci as S. aureus.1
Additionally,  S.  intermedius has  been  falsely
identified as MRSA on the basis of the pheno-
typic  PB2  latex  agglutination  test  which  has
otherwise  good  performance  for  detection  of
methicillin  resistant  S.  aureus and  coagulase
negative Staphylococci.15 Talan et al. found that
100% of S. aureus isolates were coagulase posi-
tive at 4 hours compared to only 26% of S. inter-
medius isolates.4 Thus, microbiology personnel
should suspect SIG when coagulase tests pro-
ceed more slowly than normal and there is high
clinical suspicion, such as history of an animal
bite. The presence of SIGcan then be confirmed
through  additional  biochemical  tests:  SIG  is
pyrrolidonyl  arylamidase  and  β-galactosidase
positive in contrast to S.aureus.4,25 More recent-
ly, Sasaki et al. found that S. intermedius can be
chemically  distinguished  from  S.  pseudinter-
medius by  positive  arginine  dihydrolase  and
acid production from beta-gentiobiose and D-
mannitol.22 The two species can also be distin-
guished using molecular and genetic testing, as
well  as  MALDI-TOF  mass  spectrometry,
although this is not commonly done.24,26
Case Report
A 73 year old Caucasian female with a histo-
ry of severe osteoarthritis developed fever, pain,
redness,  and  swelling  of  her  left  elbow  one
month  following  a  revision  left  elbow  total
arthroplasty. The original arthroplasty 10 years
earlier had been complicated by infection that
was successfully treated with several weeks of
intravenous antibiotics according to the patient;
the details of this remote infection and treat-
ment were unattainable. She was subsequently
well  for  many  years  without  antibiotics  until
about 2 years prior to presentation when she
began  to  develop  gradually  progressive  joint
instability and pain. She was admitted for elec-
tive  total  arthroplasty  of  the  left  elbow.
Following  surgery,  she  noted  continuous
serosanguinous drainage. Her orthopedist aspi-
rated the joint on post-operative day 22. The
joint fluid was described as cloudy with 26,000
red blood cells, 1300 white blood cells and 31%
neutrophils. No organisms were seen on Gram
stain,  and  bacterial  cultures  were  negative.
Patient was not started on antibiotics at this
time. A few days later (post-operative day 25)
she developed progressive elbow pain and fever
and was admitted to the hospital. On admission,
her  temperature  was  102.2oF  and  her  white
blood cell count was 11,000 cells/mm3. 
On surgical exploration, a large fluid collec-
tion was found in the elbow. The joint capsule
appeared intact, however both wound and joint
fluid cultures grew S. intermedius, as identi-
fied  by  the  Vitek  II  automated  microbiology
system  without  further  subspeciation.  The
wound was irrigated but the elbow prosthesis
was not removed. Blood cultures were nega-
tive. In accordance with CLSI standards, the
elbow isolates were determined to be resistant
to penicillin and tetracycline but susceptible to
oxacillin, erythromycin, clindamycin, chloram-
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phenicol,  gentamicin,  rifampin,  levofloxacin,
linezolid,  and  vancomycin.  The  patient  was
treated  with  intravenous  cefazolin  and
rifampin for six weeks and then transitioned to
oral levofloxacin and rifampin with plan for a
prolonged course given retention of infected
prosthesis. She has not had any recrudescence
of disease after 10 months on this regimen and
will  be  reevaluated  for  possible  cessation  of
therapy at one year’s time. 
The patient was an avid dog lover. Although
she did not recall her dog licking or biting her
elbow after surgery, she did report that her dog
frequently licked her face. She admitted to fre-
quent  close  contact  with  her  dog  including
sharing  her  bed  at  night.  She  denied  any
recent illness or skin lesions in her dog. 
Discussion
Human SIG infections are rarely reported.
We conducted a literature review by searching
PubMed using the terms Staphylococcus inter-
medius, S. intermedius, Staphylococcus delphi-
ni, Staphylococcus pseudintermedius, infection
and human. References cited in these articles
were also examined. Only articles published in
English  were  reviewed,  and  only  invasive
infections  were  included  in  this  discussion.
The  documented  outbreak  of  S.  intermedius
related  food-borne  illness  was  excluded  as
additional clinical information on the individ-
ual cases was not available. 
We found 17 published articles documenting
29 SIG infections in humans, 25 with S. inter-
medius and 4 with S. pseudintermedius. There
were  no  published  cases  of  S.  delphini in
humans. All 29 cases are outlined in Table 1,
with asterisks marking cases of S. pseudinter-
medius. Notably, S. intermedius and S. pseudin-
termedius were  initially  misidentified  as  S.
aureus in 34% of 29 cases. Seven of 29 cases
(24%)  were  reported  to  be  polymicrobial  by
Gram stain, culture, or PCR restriction frag-
ment length polymorphism. Four of the seven
polymicrobial  cases  occurred  in  dog  bite
wounds, and one occurred in a patient with
known dog exposure.
S.  intermedius was  first  described  as  a
human pathogen in dog bite wounds by Talan
in 1989.4 Overall, 23 of the 29 (79%) of report-
ed  cases  involved  dog  bites  (11  cases),  cat
bites (one case), or dog or cat exposure with-
out documented bites (11 cases).8-11,19,27-29 The
rate  of  S.  intermedius infection  in  dog  bite
infection  case  series  ranged  from  two  to
21%.10,11 Three of the 11 cases in patients with-
out documented bites but with dog or cat expo-
sure were delayed surgical site infections: one
case  of  sinusitis  eight  months  after  a
transsphenoidal resection of a pituitary adeno-
ma, one case of mastoiditis seven years after a
mastoidectomy,  and  one  case  of  a  surgical
wound  infection  five  weeks  after  sinus  sur-
gery.13,16,27 These cases suggest that alteration
of local host defenses may be a risk factor for
inoculation without a bite. 
Six  of  the  29  cases  (21%)  in  this  series
occurred  in  patients  without  known  animal
exposures suggesting that humans can carry
this organism in the absence of animal pres-
sure.12,15,17,18,30 In  one  case,  an  intravenous
cocaine user accustomed to licking his syringe
prior to injection developed skin abscesses.18
Notably, screening series have variously found
S. intermedius in five of 56 (9%) human sub-
jects’ oral flora, and five of 17 (29%) subjects’
skin flora.31,32 Nonetheless, other staphylococ-
cal species are much more common: S. inter-
medius constituted only 23 of 375 staphylococ-
cal isolates from the skin of 17 individuals.32 
Interestingly, regular contact with animals in
and of itself does not appear to increase the
rate of colonization. Talan et al. only found S.
intermedius in the nasopharyngeal flora of one
out of 144 healthy veterinary workers.33 Similar
studies on S. pseudintermedius have detected
the methicillin-resistant strain of the organism
Case Report
Table 2. Antibiotic susceptibilities across cases reviewed.
Isolates tested Isolates susceptible (%)
Aminoglycosides 23 18 (78%)
Amikacin 1 0 (0%)
Erythromycin 10 7 (70%)
Gentamicin 10 10 (100%)
Kanamycin 1 1 (100%)
Streptomycin 1 0 (0%)
Cephalosporins 8 5 (63%)
Cefazolin 7 5 (71%)
Cefotaxime 1 0 (0%)
Glycopeptides 12 12 (100%)
Teicoplanin 1 1 (100%)
Vancomycin 11 11 (100%)
Lincosamides 10 7 (70%)
Clindamycin 9 6 (66%)
Lincomycin 1 1 (100%)
Penicillins 35 22 (63%)
Amoxicillin-clavulanate 4 4 (100%)
Ampicillin-sulbactam 5 4 (80%)
Flucloxacillin 1 1 (100%)
Methicillin 2 1 (50%)
Oxacillin 10 8 (80%)
Penicillin 13 4 (31%)
Quinolones 14 12 (86%)
Ciprofloxacin 5 5 (100%)
Levofloxacin 7 6 (86%)
Ofloxacin 1 0 (0%)
Pefloxacin 1 1 (100%)
Streptogramins 2 1 (50%)
Pristinamycin 1 1 (100%)
Quinupristin/dalfopristin 1 0 (0%)
Tetracyclines 9 4 (44%)
Doxycycline 2 1 (50%)
Minocycline 1 1 (100%)
Tetracycline 6 2 (33%)
Other
Chloramphenicol 2 2 (100%)
Colistin 1 0 (0%)
Fosfomycin 1 1 (100%)
Fusidic acid 1 1 (100%)
Linezolid 1 1 (100%)
Mupirocin 1 1 (100%)
Nitrofurantoin 3 3 (100%)
Rifampin 3 3 (100%)
Trimethoprim-sulfamathoxazole 8 7 (88%)
Method of susceptibility testing was not reported in 11 of 17 articles reviewed. Reported methods included the automated Vitek system,
Phoenix automated system, disc diffusion testing, manual dilution testing. Only two published reports referenced CLSI guidelines. [page 10] [Infectious Disease Reports 2013; 5:e3]
in 3-5% of samples from owners of pets with
recent  S.  intermedius clinical  infection  and
seven of 128 (5%) veterinarians.34-36 There are
data,  however,  to  suggest  that  transient
increases in dogs’ bacterial load may increase
the  risk  of  transmission  to  humans.
Guardabassi et al. found antimicrobial-resist-
ant S. intermedius strains in six of 13 dog own-
ers whose pets were being treated for pyoder-
ma.37 The owners’ strains were mostly identical
to those found in their dogs. However, S. inter-
medius was no longer present in these same
dog owners two months later, suggesting that
human acquisition might be transiently related
to increased colonization pressure or antibiotic
exposure when their pets are acutely ill.
Only  three  pet-related  cases  confirmed
matching  S.  intermedius strains  between
patient  and  dog  via  pulse  field  gel  electro-
pheresis and PCR restriction fragment length
polymorphism. In two of the cases, the patient
reported a history of dog licks at the site of
infection.  Our  patient  did  not  recall  any
episodes  of  her  dog  licking  her  wound,  but
transmission  could  have  occurred  through
direct inoculation of the wound from contact
with her dog’s skin or indirectly through colo-
nization of the patient followed by invasion of
the wound.3
Treatment of SIG infections in humans has
been largely directed by the site of infection
and  antibiotic  susceptibilities.  In  the  cases
reviewed, treatment courses ranged from four
days of topical antibiotics for otitis externa to
eight  weeks  of  intravenous  antibiotics  for
brain  abscess.14,17 Susceptibility  patterns  are
documented  in  Table  2.  Three  reports  per-
formed testing for the mecA gene, with three
of four cases being negative.15,27,30 Guardabassi
et  al.  suggest  that  pets  may  facilitate  the
spread of resistance genes, serving as reser-
voirs, and resistance patterns in human infec-
tions may reflect increasing use of antibiotics
in pets.37 In all except one case, patients had
complete recovery after treatment: one individ-
ual with a S. intermedius brain abscess report-
ed  minor  residual  hemiparesis  following
antibiotic treatment but no recrudescent infec-
tion.17 Our patient is the first reported case of
mechanical  prosthesis  infection.  Despite
retention of prosthesis, our patient has been
clinically well thus far following six weeks of
induction therapy with cefazolin and rifampin
followed by 10 months of oral levofloxacin and
rifampin to date. 
Conclusions
To the best of our knowledge, this is the first
reported human case of mechanical prosthesis
infection  with  a  SIG  organism,  the  second
reported  case  of  infection  in  the  immediate
post-operative period, and only the fourth case
of  a  SIG  post-surgical  wound  infection.  The
actual  incidence  may  be  higher  due  to
misidentification  of  S.  intermedius and  S.
pseudintermedius as S. aureus. Immune status
does not appear to be a factor in SIG infection,
and  infections  can  be  monomicrobial  or
polymicrobial.  Overall,  infections  seem  to
respond well to therapy guided by susceptibili-
ty tests. The possibility of direct transmission
of a pathogenic organism from a pet to a post-
surgical wound suggests that surgical patients
may need to be warned to limit direct contact
with pets, particularly dogs, during recovery.
However,  more  studies  confirming  matching
strains between pets and owners are needed to
establish direct transmission in the setting of
human infection.
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